In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Atricure (ATRC – Research Report). The company’s shares closed yesterday at $35.48.
According to TipRanks, Kalia is a 4-star analyst with an average return of 4.7% and a 51.47% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Resmed, and Silk Road Medical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atricure with a $53.57 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $59.61 and a one-year low of $32.27. Currently, Atricure has an average volume of 436.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atricure (ATRC) Company Description:
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
Read More on ATRC:
- AtriCure says ‘welcomes’ competition from Medtronic
- Medtronic launch could create an overhang on AtriCure, says Needham
- Medtronic launches Penditure Left Atrial Appendage Exclusion System in U.S.
- AtriCure price target lowered to $49 from $68 at Needham
- AtriCure price target lowered to $45 from $79 at Canaccord
